



Projects · NTHRYS Biotech Labs

Immunology > Immunotherapy for Hematological Malignancies

Immunotherapy for Hematological Malignancies

Immunology Project Category

Contact +91-8977624748 for joining process

Visit ASCEND Portal for more details →

Explore focused-area projects under Immunotherapy for Hematological Malignancies, part of Immunology at NTHRYS Biotech Labs.

FOCUSED AREAS

CD19-Targeted CAR-T Cell Therapy Biology

Characterizing CD19 CAR-T cell expansion, persistence, and mechanisms of complete remission in B cell malignancies.

BCMA-Targeted Therapy for Multiple Myeloma

Studying BCMA-targeting CAR-T cells, bispecific antibodies, and ADCs and mechanisms of response and resistance.

CD20 Antibody Therapy Resistance Mechanisms

Investigating rituximab resistance mechanisms including CD20 downregulation, complement inhibition, and rituximab binding interference.

Allogeneic T Cell Immunotherapy for Leukemia

Developing and characterizing allogeneic off-the-shelf T cell products including gene-edited approaches for leukemia treatment.

PD-1/PD-L1 Checkpoint Inhibitor Biomarker Discovery Platform

Commercial diagnostic SaaS platform that identifies predictive biomarkers for PD-1/PD-L1 immunotherapy response in lymphoma and leukemia patients. Enables personalized treatment selection and improves clinical trial enrollment, generating recurring licensing revenue from oncology centers and pharmaceutical companies.

Dual-Antigen CAR-T Manufacturing Scale-Up Technology

Proprietary manufacturing automation tool that optimizes production of dual-targeted CAR-T cells against multiple hematologic malignancy antigens. Reduces manufacturing costs by 40% and accelerates time-to-clinic, creating substantial cost-of-goods advantages and licensing opportunities for GMP-compliant cell therapy facilities.

Bispecific Antibody Therapeutic Pipeline Asset Portfolio Manager

Enterprise software platform that tracks and optimizes bispecific antibody development programs targeting T-cell engagers for hematological malignancies. Streamlines R&D decision-making and portfolio allocation, reducing development timelines and generating recurring SaaS revenue from biopharma and CRO organizations.

NK Cell Expansion and Cryopreservation Service Solutions

Outsourced GMP manufacturing and preservation service for clinically-grade natural killer cell expansion targeting AML, CLL, and multiple myeloma. Delivers a standardized, off-the-shelf cellular product with recurring service contracts and milestone payments from cancer centers and immunotherapy companies.

Immunotherapy Toxicity Prediction and Management Software

AI-powered clinical decision support tool that predicts cytokine release syndrome and immune-related adverse events in CAR-T and checkpoint inhibitor therapies. Reduces hospital readmissions and improves patient safety outcomes, generating subscription revenue from hospital networks and managed care organizations.

Tumor-Infiltrating Lymphocite Isolation and Expansion Product Line

Specialized reagent kit and bioreactor consumables for TIL manufacturing in hematological and solid tumor applications with improved clinical efficacy. Establishes recurring product revenue streams from cancer immunotherapy centers and supports broader cell therapy commercialization partnerships.